Exicure (NASDAQ:XCUR) Shares Down 0.8% – Here’s What Happened

Exicure, Inc. (NASDAQ:XCUR)’s stock price traded down 0.8% on Thursday. The company traded as low as $1.2150 and last traded at $1.23. Approximately 22,873 shares were traded during trading, a decline of 38% from the average session volume of 37,063 shares. The stock had previously closed at $1.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure currently has a consensus rating of “Sell”.

Exicure Price Performance

The firm’s 50-day moving average price is $1.42 and its 200-day moving average price is $2.59. The company has a market cap of $8.06 million, a price-to-earnings ratio of -0.93 and a beta of 3.63.

Exicure (NASDAQ:XCUR) last posted its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.42.

Exicure Company Profile

Exicure, Inc was a biotechnology company focused on developing therapeutics based on its spherical nucleic acid (SNA) technology. The company’s platform was designed to deliver nucleic acids into cells and tissues, with the goal of regulating disease-related genes and proteins.

Exicure’s research programs addressed conditions in dermatology, immunology and other therapeutic areas. Its development portfolio included candidates such as AST-005, an SNA-based therapy investigated for psoriasis, along with programs targeting inflammatory and genetic diseases.